Morgan Stanley
BTTX

Morgan Stanley’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Morgan Stanley’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-93,973
Closed -$147K – 7973
2022
Q2 		$147K Buy
93,973
+93,964
+1,044,044% +$157K ﹤0.01% 6054
2022
Q1 		$0 Sell
9
-11
-55% -$38 ﹤0.01% 8200
2021
Q4 		$0 Buy
+20
New +$164 ﹤0.01% 8180

Other funds holding BTTX

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's BTTX Position: Q3 2022 in Review

Morgan Stanley sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q3 2022, closing a stake of 93,973 shares — an estimated $147K sold.

Morgan Stanley first reported a position in BTTX in Q4 2021 and held it in 3 quarters. The position peaked at $147K in Q2 2022. 16 funds tracked by Wall St. Rank hold BTTX as of Q3 2022.

  • Morgan Stanley reported no remaining Better Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Morgan Stanley sold 93,973 Better Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $147K.
  • Morgan Stanley first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Morgan Stanley's Better Therapeutics, Inc. Common Stock position peaked at $147K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Morgan Stanley's 13F filing for Q3 2022, filed 14 Nov 2022.